AG真人官方

Adagene to Participate in Two Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc.聽(鈥淎dagene or the Company鈥�) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies,听today announced that Adagene鈥檚 Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.

H.C. Wainwright 27th Annual Global Investment Conference

• Fireside Chat Date: Monday, September 8
• Fireside Chat Time: 11:00 AM (Eastern Time)
• Location: Lotte New York Palace Hotel
• Webcast: https://journey.ct.events/view/5c4a1cf5-b8ef-4b48-ae46-3a0f5912b3ca

Morgan Stanley 23rd Annual Global Healthcare Conference

• Fireside Chat Date: Wednesday, September 10
• Fireside Chat Time: 7:00 AM (Eastern Time)
• Location: Sheraton New York Times Square Hotel
• Webcast: https://cc.webcasts.com/morg007/090825a_js/?entity=139_6SK4L3R

A webcast of the presentations will be accessible in the section of the company鈥檚 website at for at least 30 days.

础产辞耻迟听础诲补驳别苍别
Adagene Inc.聽(Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.聽Adagene聽combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody^庐聽precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary聽Dynamic Precision Library聽(DPL) platform, composed of NEObody鈩�, SAFEbody, and POWERbody鈩� technologies, Adagene鈥檚 highly differentiated pipeline features novel immunotherapy programs. The company鈥檚 SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene鈥檚 lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit:聽.

Follow Adagene聽on ,听听补苍诲听.

SAFEbody^庐聽is a registered trademark in聽the聽United States,听China,听Australia,听Japan,听Singapore, and the聽European Union.

Investor Contacts:

Raymond Tam

Corey Davis
LifeSci Advisors